Dermatologic events from EGFR inhibitors: the issue of the missing patient voice-Reference-Cited by-同舟云学术

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice

Published:2016-10-07 Issue:2 Volume:25 Page:651-660
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Tischer Bernd,Huber Renate,Kraemer Matthias,Lacouture Mario E.

Funder

Merck KGaA

NIH/Cancer Center Support Grant

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-016-3419-4.pdf

Reference74 articles.

1. Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362:865–869

2. Alberta Health Services (2012) Prevention and treatment of rash in patients treated with EGFR inhibitor therapies. Clinical Practice Guidelines SUPP-003, v1. http://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-supp003-egfri-rash.pdf . Accessed 12/15 2016

3. Balagula Y, Lacouture ME, Cotliar JA (2010) Dermatologic toxicities of targeted anticancer therapies. J Support Oncol 8:149–161

4. Tan EH, Chan A (2009) Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother 43:1658–1666

5. Lacouture ME (2014) Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair and Nails in Cancer Patients. John Wiley & Sons, Hoboken

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Preliminary Study Examining the Correlation between EGFRI Treatment, Clinic Dermatoscopy Features, and Serum Levels of Anti-Alpha-Galactosyl IgE in Colorectal Cancer Patients;Gastroenterology Insights;2024-06-17

2. The state of the art in secondary pharmacology and its impact on the safety of new medicines;Nature Reviews Drug Discovery;2024-05-21

3. Patient symptoms, self-management, and unscheduled healthcare use during the first 6 months of targeted oral anticancer agent therapy: protocol for a mixed-methods US study;BMJ Open;2024-02

4. Quality of Life Impact in Patients with Cutaneous Toxicities Caused by Epidermal Growth Factor Receptor Inhibitors and Immunotherapy;Dermatology;2024

5. Voice of persons with a life-limiting illness in conversation with healthcare professionals: systematic review and meta-synthesis;BMJ Supportive & Palliative Care;2023-05-17